ABI-5366 / Assembly Biosci - LARVOL DELTA

Preclinical profile of ABI-5366, a novel potent HSV helicase-primase inhibitor, with potential for weekly or monthly oral dosing for the treatment of recurrent genital herpes (ESCMID Global 2025) - No abstract available

Preclinical • Infectious Disease

The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participants (ESCMID Global 2025) - No abstract available

Clinical • P1 data • PK/PD data

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes (clinicaltrials.gov) - P1 | N=146 | Recruiting | Sponsor: Assembly Biosciences | Not yet recruiting ➔ Recruiting

Enrollment open • Herpes Simplex • Infectious Disease

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes (clinicaltrials.gov) - P1 | N=146 | Not yet recruiting | Sponsor: Assembly Biosciences

New P1 trial • Herpes Simplex • Infectious Disease